LifeStance Health Group, Inc. (LFST) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates positive financial performance, with strong revenue growth, improved margins, and meaningful free cash flow expected. The Q&A section reveals positive analyst sentiment, with new productivity initiatives, a strong pipeline for center openings, and a focus on leveraging AI and technology. The company also announced plans for new centers and specialty services expansion. Despite some uncertainties in clinician retention and real-time patient tracking, the overall sentiment is positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue $403 million, a 21% increase year-over-year. The growth was driven by better-than-expected total revenue per visit and visit volumes, with visit volumes increasing 18% and total revenue per visit increasing 3%.
Visit Volumes 2.5 million, an 18% increase year-over-year. This was driven by better-than-expected clinician productivity and net clinician additions.
Total Revenue Per Visit $163, a 3% increase year-over-year. This was modestly ahead of expectations.
Visits Per Average Clinician Increased 7% year-over-year for the second consecutive quarter. This was achieved while adding 309 clinicians in the first quarter, representing an 11% growth in the clinician base.
Center Margin $136 million, a 24% increase year-over-year, representing 33.7% as a percentage of revenue. The increase was primarily due to the revenue beat and lower spending in center costs.
Adjusted EBITDA $51 million, a 48% increase year-over-year, representing 12.7% as a percentage of revenue. The outperformance was attributable to favorable Center Margin.
Net Income $14 million, compared to $1 million last year. This reflects significant improvement in profitability.
Free Cash Flow $22 million, an improvement of $32 million from the first quarter of last year.
Cash Position $195 million, reflecting $49 million deployed towards share repurchases during the quarter.
Net Long-Term Debt $263 million, with net leverage of 0.5x and gross leverage of 1.6x.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-enabled scheduling tools: Implemented to improve patient access and increase conversion of calls to appointments.
AI-assisted clinical documentation: Rolled out to reduce administrative burden for clinicians, enabling more patient interaction and improving satisfaction.
New EHR system: Selected a best-in-class vendor with implementation starting this year and transition planned for 2027.
Geographic expansion: Opened 2 new markets through acquisitions, adding high-quality practices to support future growth.
Tuck-in acquisitions: Resumed M&A activities with a disciplined approach, establishing a pipeline for future acquisitions.
Revenue growth: Achieved 21% growth in revenue, reaching $403 million in Q1 2026.
Clinician productivity: Improved year-over-year, contributing to operational efficiency and better patient outcomes.
Digital and AI tools: Applied to enhance operational efficiency, including digital patient check-in and robotic process automation.
Focus on clinical excellence: Published outcomes showing 75% of patients experienced significant improvements in anxiety and depression.
Financial flexibility: Maintained a strong balance sheet with $195 million in cash and net leverage of 0.5x, supporting strategic priorities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Compliance Risks: The company acknowledges risks related to forward-looking statements and uncertainties as noted in their SEC filings, which could materially impact actual results.
Technological Transition Risks: The transition to a new EHR system, expected to occur during 2027, poses risks related to organizational readiness, clinician engagement, and potential disruptions during implementation.
M&A Execution Risks: The company’s strategy to expand through tuck-in acquisitions carries risks of integration challenges and alignment with the company’s model and culture.
Economic and Market Risks: Shifts in patient payment preferences from cash pay to insurance coverage could impact revenue dynamics and operational adjustments.
Operational Efficiency Risks: The reliance on AI and digital tools for operational efficiency, such as scheduling and clinical documentation, may face challenges in adoption, effectiveness, and clinician satisfaction.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Revenue Guidance: The company has raised its revenue range by $25 million at the midpoint to $1.64 billion to $1.68 billion, implying a growth rate of 17%.
Full Year 2026 Center Margin Guidance: The Center Margin range has been raised by $21 million at the midpoint to $547 million to $571 million.
Full Year 2026 Adjusted EBITDA Guidance: The adjusted EBITDA range has been raised by $15 million at the midpoint to $200 million to $220 million, implying a margin as a percentage of revenue of 12.7%, representing over 150 basis points of margin expansion year-over-year.
Second Quarter 2026 Guidance: Revenue is expected to range from $405 million to $425 million; Center Margin is expected to range from $135 million to $147 million; and adjusted EBITDA is expected to range from $50 million to $60 million.
Long-Term Revenue Growth Outlook: The company expects annual revenue growth in the mid-teens beyond 2026.
Long-Term Adjusted EBITDA Margin Outlook: The company aims to achieve mid-teens adjusted EBITDA margins by full year 2028.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: $49 million deployed towards share repurchases during the quarter following the Board's $100 million authorization in February.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Clinician growth was a bit above expectations in the quarter. What tailwinds contributed to this growth, and what strategies are being used to attract and retain clinicians?
A:The clinician growth was driven by strong recruiting efforts and stable retention. Over 300 clinicians were added, and productivity improved by 7% year-over-year. No new factors were identified as contributing to this growth.
Q:How does the company envision technology and AI contributing to achieving long-term EBITDA margins of 15% to 20%?
A:Technology and AI are key levers for achieving long-term margins. The company aims to hit mid-teens adjusted EBITDA margins by 2028 through center margin expansion and leveraging G&A expenses via AI enablement and technological initiatives.
Q:Are there new productivity initiatives planned, or is the focus on existing initiatives?
A:The company is continuing to execute on existing productivity initiatives while exploring new opportunities. The focus remains on balancing the use of existing clinician capacity with hiring new clinicians, with productivity being complementary to clinician growth.
Q:Given the strong visit growth in Q1, how should we think about visit growth for the rest of the year?
A:Visit growth guidance is in the low double digits for the rest of the year. The company expects a more normal revenue pattern with modestly higher second-half revenue. Productivity gains are expected to stabilize as initiatives mature.
Q:What is the source of the 309 clinician adds in the quarter, and how much is attributable to tuck-in acquisitions?
A:The majority of the 309 clinician adds were from organic hiring, with stable retention. Tuck-in acquisitions contributed modestly. Clinicians came from three main sources: small private practices, salaried positions at hospitals, and new graduates.
Q:What factors contribute to the EBITDA guidance and margin consistency for the year?
A:The EBITDA guidance reflects a $6 million increase in G&A expenses, driven by investments in AI, technology, and patient acquisition. The margin consistency is supported by leveraging technology and maintaining efficient spending.
Q:How is the company improving the conversion of prospective patients to booked appointments?
A:The company has rolled out a new Care Matching algorithm, improving conversion rates by 5%. This tool will be fully implemented nationwide in the coming months, with further exploration planned to reduce friction in the patient experience.
Q:Does the company track patient health improvement metrics, and is there an app for real-time tracking?
A:The company tracks patient health improvement through monthly surveys on anxiety and depression. There is no app for real-time tracking, but the company is exploring options to support patients between visits.
Q:How does the company leverage its outcome study findings?
A:The outcome study findings are used to improve patient care, establish trust with referral partners, and demonstrate quality outcomes to payers. This supports competitive differentiation and payer negotiations.
Q:Have the productivity enhancements impacted clinician retention or churn?
A:It is too early to determine the impact on clinician retention or churn. Anecdotal feedback from clinicians has been positive, but retention remains stable.
Q:What drives the care margin improvement implied in the guidance?
A:Care margin improvement is driven by rate increases, operating leverage from volume, and favorable spending. The margin has improved by 130 basis points year-over-year.
Q:How is the company expanding its specialty services, and what is the growth outlook?
A:Specialty services revenue is expected to grow from $50 million last year to $70 million this year, driven by neuropsych testing, TMS, and Spravato services. The company is adding new TMS chairs and Spravato sites quarterly.
Q:What is the cadence for de novo center openings and tuck-in acquisitions for the year?
A:The company plans to open 20 to 30 centers this year and has a strong pipeline of tuck-in acquisitions. De novos are primarily in adjacent towns for faster ramp-up, with some in new geographies for long-term growth.
Q:How should we think about visit rate trends for the rest of the year?
A:Visit rates are expected to grow in the low to mid-single digits, supported by payer negotiations and rate increases. The environment remains constructive for rate improvements.
Q:What is the de novo strategy, and how does productivity ramp up for new centers?
A:De novos are primarily placed in adjacent towns for quick ramp-up, with some in new geographies. Centers in adjacent towns ramp quickly due to existing referral partnerships, while new geography centers take 12 to 24 months to breakeven.
Q:Are there any changes in the competitive landscape impacting recruitment, patient volumes, or rates?
A:The industry remains highly fragmented, with no significant changes impacting recruitment, patient volumes, or rates. The company continues to perform strongly across all business aspects.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the impact of productivity enhancements on clinician retention or churn, stating it was too early to tell. Additionally, while the company is exploring the development of an app for real-time patient tracking, no concrete plans or timelines were provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI consistency
AI scheduling
AI tool
AI workflow
Center Margin
EHR ability
EHR selection
Google Stars
LifeStance increase
LifeStance need
LifeStance outcome
LifeStance position
MSAs year
Margin income
Margin mid
Margin midpoint
Margin percentage
McGroarty Chief
Officer McGroarty
Stars rating
ability AI
acquisition quality
acquisition tuck
acquisition way
addition AI
amount market
approach
balance
center
clinician base
engagement
excellence
expectation visit
healthcare
momentum
outcome satisfaction
technology
teen
tool patient
transition
visit clinician
LFST Transcript
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral5-13
LifeStance Health Group, Inc. (LFST) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary indicates positive financial performance, with strong revenue growth, improved margins, and meaningful free cash flow expected. The Q&A section reveals positive analyst sentiment, with new productivity initiatives, a strong pipeline for center openings, and a focus on leveraging AI and technology. The company also announced plans for new centers and specialty services expansion. Despite some uncertainties in clinician retention and real-time patient tracking, the overall sentiment is positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
LifeStance Health Group, Inc. (LFST) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call highlights strong financial performance with raised EBITDA guidance, anticipated revenue growth, and margin expansion. Product development and technology integration are promising, supported by AI initiatives and specialty services. The Q&A section confirms durable productivity improvements and strategic focus on efficiency and clinician retention. While some areas lack specific detail, the overall sentiment is positive, driven by constructive payer relationships and optimistic long-term growth projections. Given the small-cap nature of the stock, a positive reaction of 2% to 8% is expected over the next two weeks.
LifeStance Health Group, Inc. (LFST) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance, optimistic guidance, and strategic initiatives, such as AI investments and a partnership with Calm, indicating positive market sentiment. While there are concerns about sequential margin decline and lack of specific details on AI impact, the overall outlook remains positive with raised EBITDA guidance and expected revenue growth. The market cap suggests moderate sensitivity, leading to a predicted stock price increase of 2% to 8%.
LFST Slides
LFST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
